{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:19:19Z","timestamp":1791533959091,"version":"4.3.4"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Prostate cancer often requires frequent in-person clinical visits, imposing substantial travel, financial, and time burdens for patients. Combining telehealth with in-home monitoring (enhanced telehealth) has the potential to make care more patient centered and efficient.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the feasibility and implementation context of enhanced telehealth for patients with prostate cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Adult patients with prostate cancer receiving androgen deprivation therapy (ADT) were enrolled in this multiphase quality improvement study of enhanced telehealth from June 1, 2023, to June 30, 2024, and followed up for 8 months. The study was conducted at 7 ambulatory oncology practice sites at Memorial Sloan Kettering, an academic comprehensive cancer center. Phase 1 included semistructured interviews with key stakeholders to assess implementation considerations of enhanced telehealth. Phase 2 piloted an enhanced telehealth program offering remote blood pressure (BP) monitoring, mobile phlebotomy, and injections at home; patients could choose to participate in any available component.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Enhanced telehealth, a care delivery model that augments routine telehealth encounters with (1) home phlebotomy, (2) remote BP monitoring, and\/or (3) at-home administration of ADT or other injectable therapies.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The primary outcome was feasibility, assessed by completion rates for each enhanced telehealth component at the patient and visit levels. Patient and clinician satisfaction was assessed using the Net Promotor Score. Acceptability, appropriateness, and feasibility were measured using validated measures on a 5-point Likert scale.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Thirty-eight patients participated; the median age was 70.0 years (IQR, 61.5-76.7 years) and 24 (63.2%) had metastatic castration-sensitive prostate cancer. Patient-level completion rates for at least 1 service were telehealth, 68.4% (26 of 38); remote BP monitoring, 91.9% (34 of 37); home phlebotomy, 96.3% (26 of 27); and at-home injections, 90.0% (9 of 10). Visit-level completion rates were high for telehealth (92.3% [60 of 65]), phlebotomy (95.4% [145 of 152]), and injections (84.6% [11 of 13]) but lower for BP monitoring (65.0% [343 of 528]). Patients rated all components as acceptable (mean [SD] score, 4.8 [0.4]; range, 3.25-5), appropriate (mean [SD] score, 4.8 [0.4]; range, 3.75-5), and feasible (mean [SD] score, 4.7 [0.5]; range, 3.25-5). Enhanced telehealth had high patient and clinician satisfaction (Net Promotor Score: patients, 82.4%; clinicians, 80.0% for telehealth, 80.6% for remote BP monitoring, 84.6% for home phlebotomy, and 75.0% for home injections).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this quality improvement study, enhanced telehealth was feasible, with greater than 60% completion for all scheduled visits, with strong endorsement of benefits from patients with prostate cancer as well as clinicians. These findings support further development of enhanced telehealth.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.17466","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:30:25Z","timestamp":1781019025000},"page":"e2617466","source":"Crossref","is-referenced-by-count":3,"title":["Enhanced Telehealth in Prostate Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Erin M.","family":"Bange","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Reiner","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Liebertz","sequence":"additional","affiliation":[{"name":"Division of Advanced Practice Providers, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Malling","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad","family":"Kuperman","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Daly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Chimonas","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Marcinkowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil D.","family":"Doshi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Polubriaginof","sequence":"additional","affiliation":[{"name":"Population Health, Value & Clinical Analytics, Office of the Chief Medical Officer, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Stevanovic","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Murillo","sequence":"additional","affiliation":[{"name":"Perioperative & Specialty Pharmacy Services, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Stetson","sequence":"additional","affiliation":[{"name":"Tiger Connect, El Segundo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Schrag","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S.","family":"Panageas","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"1","key":"zoi260492r1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"zoi260492r2","doi-asserted-by":"publisher","journal-title":"J Clin Oncol","DOI":"10.1200\/JCO.19.01564"},{"issue":"3","key":"zoi260492r3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41391-021-00328-1","article-title":"Treating the patient and not just the cancer: therapeutic burden in prostate cancer.","volume":"24","author":"Spratt","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"15","key":"zoi260492r4","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment.","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi260492r5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068997","article-title":"Treatment burden in survivors of prostate and colorectal cancers: a qualitative interview study.","volume":"13","author":"Adam","year":"2023","journal-title":"BMJ Open"},{"issue":"8","key":"zoi260492r6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamaoncol.2020.1475","article-title":"Assessment of parking fees at National Cancer Institute\u2013designated cancer treatment centers.","volume":"6","author":"Lee","year":"2020","journal-title":"JAMA Oncol"},{"key":"zoi260492r7","doi-asserted-by":"publisher","DOI":"10.2196\/43404","article-title":"Advancing digital health innovation in oncology: priorities for high-value digital transformation in cancer care.","volume":"25","author":"Patel","year":"2023","journal-title":"J Med Internet Res"},{"issue":"4","key":"zoi260492r8","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1002\/onco.13676","article-title":"Rapid implementation of telemedicine during the COVID-19 pandemic: perspectives and preferences of patients with cancer.","volume":"26","author":"Hasson","year":"2021","journal-title":"Oncologist"},{"issue":"7","key":"zoi260492r9","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00040","article-title":"Cancer patients\u2019 preferences and perceptions of advantages and disadvantages of telehealth visits during the COVID-19 pandemic.","volume":"7","author":"Kumar","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"3","key":"zoi260492r10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1161\/HYPERTENSIONAHA.120.14742","article-title":"Management of hypertension in the digital era: small wearable monitoring devices for remote blood pressure monitoring.","volume":"76","author":"Kario","year":"2020","journal-title":"Hypertension"},{"key":"zoi260492r11","doi-asserted-by":"publisher","author":"Bange","journal-title":"JNCI Cancer Spectr","DOI":"10.1093\/jncics\/pkae104"},{"issue":"23","key":"zoi260492r12","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer.","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi260492r13","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer.","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"2","key":"zoi260492r14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study.","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"issue":"12","key":"zoi260492r15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260492r16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer.","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"10323","key":"zoi260492r17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"zoi260492r18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2015-004480","article-title":"Explanation and elaboration of the SQUIRE (Standards for Quality Improvement Reporting Excellence) guidelines, v.2.0: examples of SQUIRE elements in the healthcare improvement literature.","volume":"25","author":"Goodman","year":"2016","journal-title":"BMJ Qual Saf"},{"issue":"6","key":"zoi260492r19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups.","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"issue":"6","key":"zoi260492r20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/tbm\/ibz085","article-title":"Using the Practical, Robust Implementation and Sustainability Model (PRISM) to qualitatively assess multilevel contextual factors to help plan, implement, evaluate, and disseminate health services programs.","volume":"9","author":"McCreight","year":"2019","journal-title":"Transl Behav Med"},{"issue":"3","key":"zoi260492r21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.9745\/GHSP-D-18-00068","article-title":"The Net Promoter Score (NPS) for insight into client experiences in sexual and reproductive health clinics.","volume":"6","author":"Koladycz","year":"2018","journal-title":"Glob Health Sci Pract"},{"issue":"1","key":"zoi260492r22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13012-017-0635-3","article-title":"Psychometric assessment of three newly developed implementation outcome measures.","volume":"12","author":"Weiner","year":"2017","journal-title":"Implement Sci"},{"issue":"5","key":"zoi260492r23","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1111\/hex.13577","article-title":"The ultimate question? evaluating the use of Net Promoter Score in healthcare: a systematic review.","volume":"25","author":"Adams","year":"2022","journal-title":"Health Expect"},{"issue":"5","key":"zoi260492r24","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1302\/0301-620X.96B5.32434","article-title":"Assessing treatment outcomes using a single question: the Net Promoter Score.","volume":"96-B","author":"Hamilton","year":"2014","journal-title":"Bone Joint J"},{"issue":"12","key":"zoi260492r25","first-page":"46","article-title":"The one number you need to grow.","volume":"81","author":"Reichheld","year":"2003","journal-title":"Harv Bus Rev"},{"issue":"3","key":"zoi260492r26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/NHH.0000000000000958","article-title":"Patient safety and satisfaction in home chemotherapy.","volume":"39","author":"Sanguinetti","year":"2021","journal-title":"Home Healthc Now"},{"issue":"2","key":"zoi260492r27","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000434","article-title":"Moving cancer care closer to home: a single-centre experience of home chemotherapy administration for patients with myelodysplastic syndrome.","volume":"4","author":"Murthy","year":"2019","journal-title":"ESMO Open"},{"issue":"5","key":"zoi260492r28","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/ecc.12408","article-title":"A multi-method review of home-based chemotherapy.","volume":"25","author":"Evans","year":"2016","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"6","key":"zoi260492r29","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/bjc.2013.414","article-title":"Is community treatment best? a randomised trial comparing delivery of cancer treatment in the hospital, home and GP surgery.","volume":"109","author":"Corrie","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"zoi260492r30","article-title":"Accelerating the delivery of cancer care at home during the COVID-19 pandemic.","volume":"1","author":"Laughlin","year":"2020","journal-title":"NEJM Catalyst"},{"issue":"6","key":"zoi260492r33","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.fertnstert.2008.03.057","article-title":"Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.","volume":"91","author":"Kahraman","year":"2009","journal-title":"Fertil Steril"},{"key":"zoi260492r31","unstructured":"Saxenda. Package insert. Novo Nordisk; 2018. Accessed December 21, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206321s007lbl.pdf"},{"key":"zoi260492r32","unstructured":"Humira (adalimumab). Package insert. Abbott Laboratories; 2003. Accessed December 21, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/adalabb123102LB.htm#dose"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2850066\/bange_2026_oi_260492_1786542387.59365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:10:11Z","timestamp":1787065811000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2850066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.17466","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}